Diagnostic Medicine in Brazil Current Behavior Changes Analysis¶
Ongoing Behavior Changes¶
Based on the synthesis of the provided reports on the Brazilian Diagnostic Medicine industry's value chain, final customers, and current demand behavior, several ongoing behavior changes are significantly impacting relationships and demand across the value chain in 2024 and looking into 2025.
A primary and overarching behavior change is the increasing demand for diagnostic services. Brazilians underwent 2.4 billion diagnostic exams in 2023, representing an 11% increase from 2022. The private sector alone saw a 40% growth in exam volume between 2018 and 2023, reaching 1.2 billion exams. This heightened demand signifies a behavioral shift by the final customers (patients and the entities that serve them – SUS and supplementary health operators) towards greater utilization of diagnostic testing. This is driven by factors such as a large and aging population, rising incidences of chronic diseases, increased health awareness, and advancements in medical knowledge emphasizing early diagnosis and personalized treatment.
Accompanying the increased volume is a notable behavior change among health insurance operators towards cost containment and intense negotiation on reimbursement rates. Despite the significant growth in the volume of exams, diagnostic procedures accounted for a slightly lower percentage of supplementary health expenses in 2023 (21.1%) compared to 2018 (22.9%). This indicates that while demand volume from their beneficiaries is rising, insurers are actively managing costs and exerting pressure on service providers regarding the fees paid for these procedures. This behavior creates tension in the relationships between payers and diagnostic service providers.
Within the diagnostic service provision step, a major observable behavior change is strategic consolidation through mergers and acquisitions (M&A). Large networks like Dasa and Grupo Fleury (following its merger with Hermes Pardini) are expanding their market presence and capabilities by acquiring smaller players. This behavior is driven by a desire to gain economies of scale, increase negotiating leverage with both suppliers and payers, expand geographic reach, and integrate services. This fundamentally alters the competitive landscape and the relationships between large networks and independent laboratories.
There is also a growing behavior among diagnostic service providers to invest in and adopt new technologies. The overall market for medical devices and in-vitro diagnostics, representing the tools used by providers, grew by 57.9% between 2018 and 2023. This investment behavior is a response to the need to meet increasing demand, improve efficiency, expand test menus, offer more complex and specialized diagnostics (like molecular and genetic testing), and remain competitive in a consolidating market. This is highlighted by trends for 2025 focusing on innovation and efficiency.
Furthermore, some large diagnostic service providers are exhibiting a behavior of expanding their B2B service offerings. Afip Medicina Diagnóstica, traditionally a major provider for the SUS, launched a business unit specifically to support hospitals and other laboratories. Large private networks also engage in lab-to-lab (L2L) services. This behavioral shift aims to leverage existing infrastructure and expertise to create new revenue streams and deepen relationships with other healthcare entities.
Finally, there is an ongoing behavior of adaptation to evolving regulatory requirements across the entire value chain. Compliance with regulations such as ANVISA's RDC 786/2023 for clinical laboratories and the General Data Protection Law (LGPD) requires continuous effort and investment from manufacturers, distributors, and especially service providers, impacting operational procedures, IT systems, and costs. This behavior is mandatory and shapes how all players conduct their activities and interact with regulatory bodies.
Impact of Behavior Changes on the Value Chain¶
| Value Chain Step | Ongoing Behavior Change Impacting This Step | Impact on Relationships | Impact on Demand |
|---|---|---|---|
| Research, Development, and Manufacturing | Increased demand for diagnostic products, Increased investment in Medical Devices/IVD, Consolidation among Service Providers (customers), Technological Adoption, Regulatory Adaptation | Strengthened relationships with large, consolidating service providers; increased negotiation pressure from larger customers. Increased collaboration/partnership with R&D institutions for new technologies. Compliance requirements shape interactions with ANVISA. | Increased demand for higher volumes of existing products. Growing demand for new, advanced, and high-throughput equipment and reagents driven by technological adoption and expansion of test menus by service providers. |
| Distribution and Commercialization | Increased volume of diagnostic products, Consolidation among Service Providers (customers), Increased investment in Medical Devices/IVD, Regulatory Adaptation | Pressure on distribution margins from larger, consolidated customers. Increased demand for efficient, reliable logistics (especially cold chain) and technical support. Compliance requirements shape handling and storage interactions. | Increased demand for distribution services for higher volumes of products. Demand for distribution capabilities supporting specialized products and technologies acquired through increased investment by providers. |
| Diagnostic Service Provision | Increasing demand for services, Cost containment by Health Insurance Operators, Strategic Consolidation, Increased Investment in Medical Devices/IVD, Expansion of B2B Services, Regulatory Adaptation, Technological Adoption | More intense and often contentious relationships with health insurance operators due to reimbursement pressure and negotiation. Increased competition among large networks; potential for strained relationships with smaller independent labs. New B2B relationships with hospitals and other labs. Compliance requirements shape interactions with regulatory bodies and impact internal operations. | Direct increase in the volume of tests and procedures demanded by patients (mediated by payers/physicians). Growing demand for a wider range of specialized tests due to technological adoption. Demand for B2B services from other healthcare entities. |
| Healthcare Service Delivery & Utilization | Increasing demand for services, Cost containment by Health Insurance Operators, Strategic Consolidation (affecting access points), Technological Adoption | Relationships between patients/physicians and service providers influenced by network coverage (supplementary health), waiting times (SUS), and accessibility of services. Relationships between insurers and beneficiaries impacted by coverage limitations driven by cost containment. | Higher volume of patients seeking diagnostic services. Demand for more convenient access points and integrated service offerings (influenced by consolidation). Demand for access to new and advanced diagnostic tests. |
| Financing and Reimbursement | Increasing demand for services, Cost containment by Health Insurance Operators, Strategic Consolidation (affecting negotiation power) | Intensified negotiation and potential conflict in relationships between health insurance operators and diagnostic service providers over reimbursement rates and payment terms. Continued financial pressure on providers serving the SUS due to low reimbursement. | Increased financial outflow from payers (SUS, Supplementary Health) to cover the rising volume of diagnostic exams. Pressure from payers to slow the growth of spending despite volume increases. |
| Regulation and Oversight | Increasing demand and technological adoption (increasing complexity), Strategic Consolidation (potential market impact) | Increased interaction and compliance requirements between regulatory bodies (ANVISA, ANS) and all players in the value chain. Potential for regulatory scrutiny regarding market concentration and competition. | Not a direct impact on demand volume, but regulatory changes can influence the types of tests available and the standards of service delivery, indirectly shaping what can be demanded and provided legally and safely. |
References¶
- Afip: Afip lança unidade de negócios de medicina diagnóstica. https://www.afip.com.br/afip-lanca-unidade-de-negocios-de-medicina-diagnostica/
- Associação Brasileira de Medicina Diagnóstica (Abramed): Pesquisa revela que brasileiros realizaram 2,4 bilhões de exames de diagnóstico em 2023. https://abramed.org.br/pesquisa-revela-que-brasileiros-realizaram-24-bilhoes-de-exames-de-diagnostico-em-2023/
- Conrad: Perspectivas da medicina diagnóstica para 2025. https://conradweb.com.br/perspectivas-da-medicina-diagnostica-para-2025/
- Estadão: Fusões e aquisições no setor de saúde disparam no 1º trimestre, diz PwC. https://www.estadao.com.br/economia/fusoes-e-aquisicoes-no-setor-de-saude-disparam-no-1-trimestre-diz-pwc/
- FGV EAESP: Impacto Da Criação Da Associação Brasileira De Medicina Diagnóstica (Abramed) Como Estratégia De Competitividade No Setor Privado De Serviços Diagnósticos No Brasil. https://bibliotecadigital.fgv.br/dspace/handle/10438/18544
- Futuro da Saúde: Medicina diagnóstica: o que esperar do setor nos próximos anos. https://futurodasude.com.br/medicina-diagnostica-o-que-esperar-do-setor/
- Hospital São Paulo: Saúde Suplementar. https://hospitalsaopaulo.org.br/saude-suplementar
- Interfarma: Medicina diagnóstica tem papel decisivo na saúde suplementar. https://interfarma.org.br/noticias/medicina-diagnostica-tem-papel-decisivo-na-saude-suplementar
- Medicina SA: Mercado de dispositivos médicos e diagnóstico in-vitro cresceu 57,9%. https://medicinasa.com.br/mercado-dispositivos-medicos/
- Mobilemed: Tendências e desafios da Medicina Diagnóstica. https://mobilemed.com.br/tendencias-e-desafios-da-medicina-diagnostica/
- Mordor Intelligence: Tamanho do mercado de diagnóstico in vitro do Brasil e análise de ações – Tendências e previsões de crescimento (2024 - 2029). https://www.mordorintelligence.com/pt/industry-reports/brazil-in-vitro-diagnostics-market
- Percepção de Valor em Serviços de Medicina Diagnóstica. https://www.saudebusiness.com/gestao/percepcao-de-valor-em-servicos-de-medicina-diagnostica
- Revistas PUC-SP: O segmento da medicina diagnóstica no Brasil. https://revistas.pucsp.br/RFCMS/article/download/26500/18754/62758
- Saúde Business: Medicina diagnóstica: perspectivas otimistas para o próximo ano. https://www.saudebusiness.com/gestao/medicina-diagnostica-perspectivas-otimistas-para-o-proximo-ano
- Saúde Business: Fusões e aquisições no setor de saúde ganham impulso em 2024. https://www.saudebusiness.com/fusoes-e-aquisicoes/fusoes-e-aquisicoes-no-setor-de-saude-ganham-impulso-em-2024
- Shift: Tendências na medicina diagnóstica para 2025: inovação, eficiência e foco no paciente. https://medical.shift.com.br/tendencias-medicina-diagnostica-2025/
- Shopplab Notícias: O Mercado Brasileiro de Medicina Diagnóstica: um Panorama Atual. https://www.shopplab.com.br/blog/o-mercado-brasileiro-de-medicina-diagnostica-um-panorama-atual/
- Terra: Com crescimento de 25%, fusões e aquisições no setor de saúde quebram recorde. https://www.terra.com.br/economia/com-crescimento-de-25-fusoes-e-aquisicoes-no-setor-de-saude-quebram-recorde,72a1619778a872bb3f2529c7d709520by1u7137k.html
- Terra: Fusões e aquisições no setor de saúde devem crescer este ano, com foco regional, diz consultoria. https://www.terra.com.br/economia/fusao-e-aquisicao/fusoes-e-aquisicoes-no-setor-de-saude-devem-crescer-este-ano-com-foco-regional-diz-consultoria,5156b31a6f66c4244878f249604280cahc8432oq.html